Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,208,321 shares of the biopharmaceutical company’s stock after purchasing an additional 724,493 shares during the period. Nuveen Asset Management LLC’s holdings in Gilead Sciences were worth $481,093,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. Finally, Stephens Consulting LLC lifted its position in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold a total of 22,929 shares of company stock worth $2,644,895 in the last 90 days. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $98.38 on Thursday. The company’s fifty day moving average is $106.33 and its 200-day moving average is $99.50. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm has a market cap of $122.50 billion, a price-to-earnings ratio of 265.89, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the prior year, the business posted ($1.32) EPS. Gilead Sciences’s quarterly revenue was down .3% on a year-over-year basis. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.21%. Gilead Sciences’s dividend payout ratio (DPR) is 66.53%.

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Wells Fargo & Company upped their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Thursday, February 13th. Finally, The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.